

Contents

Preface XI

List of Contributors XV

1	Efavirenz®, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate	1
	<i>Nobuyoshi Yasuda and Lushi Tan</i>	
1.1	First Drug Candidate	2
1.1.1	Project Development	2
1.1.1.1	Medicinal Route	2
1.1.1.2	Process Development	3
1.1.2	Chemistry Development	10
1.1.2.1	Sugasawa Reaction	10
1.1.2.2	Asymmetric Addition of 2-Pyridinylacetylene Anion to Ketimine 5 and 17	15
1.2	Efavirenz®	19
1.2.1	Project Development	19
1.2.1.1	Medicinal Route	19
1.2.1.2	Process Development	20
1.2.2	Chemistry Development	34
1.2.2.1	Reaction Mechanism for the Lithium Acetylide Addition to <i>p</i> MB Protected Amino Ketone 41	35
1.2.2.2	Reaction Mechanism for the Zinc Acetylide Addition to Amino Ketone 36	40
1.3	Conclusion	41
	Acknowledgments	41
	References	42
2	CCR5 Receptor Antagonist	45
	<i>Nobuyoshi Yasuda</i>	
2.1	Project Development	45
2.1.1	Medicinal Route	45

2.1.2	Process Development	47
2.1.2.1	Route Selection for Cyclopentenone 2	47
2.1.2.2	Process Optimization for Preparation of 2	50
2.1.2.3	Optimization of the Preparation of Pyrazole 3	57
2.1.2.4	Optimization of the Preparation of Our Target 1 (End Game)	59
2.1.2.5	Overall Preparation Scheme	61
2.2	Chemistry Development	62
2.2.1	Kinetic Resolution	64
2.2.2	Modification of Ligands	67
2.2.3	NMR Studies Revealed the Reaction Mechanism	68
2.2.4	Additional Studies for Confirmation of the Retention–Retention Mechanism	72
2.3	Conclusion	74
	Acknowledgments	74
	References	74
3	5α-Reductase Inhibitors–The Finasteride Story	77
	<i>J. Michael Williams</i>	
3.1	Project Development	78
3.1.1	Finasteride	78
3.1.1.1	The Medicinal Chemistry Route	78
3.1.1.2	Process Development	80
3.1.2	The Second Generation Candidates	96
3.1.2.1	The Medicinal Chemistry Route	96
3.1.2.2	Process Development	97
3.2	Chemistry Development	105
3.2.1	Mechanistic Studies–the DDQ Oxidation	105
3.2.2	A New General Method for the Preparation of Weinreb Amides from Esters	112
3.3	Conclusion	113
	Acknowledgments	113
	References	113
4	Rizatriptan (Maxalt®): A 5-HT_{1D} Receptor Agonist	117
	<i>Cheng-yi Chen</i>	
4.1	Project Development	118
4.1.1	Medicinal Chemistry Route	118
4.1.1.1	Problems of the Original Route	119
4.1.1.2	Advantages of the Original Route	119
4.1.2	Process Development	119
4.1.2.1	Convergent Fisher Indole Synthesis	119
4.1.2.2	Palladium-Catalyzed Indole Synthesis	122
4.2	Chemistry Development	131
4.2.1	Application of Pd-Catalyzed Annulation to the Synthesis of the Indole Acetic Acid	131

4.2.2	New Indole Chemistry from Development of Pd Chemistry	134
4.2.2.1	Discovery of New Indole Synthesis from Amines	134
4.2.2.2	Direct Coupling of Iodoaniline with Ketone	136
4.2.2.3	Application to Laropiprant Indole Synthesis	139
4.3	Conclusion	141
	Acknowledgments	141
	References	141
5	SERM: Selective Estrogen Receptor Modulator	143
	<i>Zhiguo Jake Song</i>	
5.1	Project Development	144
5.1.1	Medicinal Route	144
5.1.1.1	Problems of the Original Route	145
5.1.2	Process Development	145
5.1.2.1	Preparation of Intermediate 15	147
5.1.2.2	Quinone Ketal Route to <i>cis</i> -Diaryl Dihydrobenzoxathiin 30	147
5.1.2.3	Benzoxathiin Reduction Route to the <i>cis</i> -Diaryl Dihydrobenzoxathiin Intermediate 12	150
5.1.2.4	Installation of Pyrrolidinyl Ethanol	155
5.1.2.5	Final Deprotection and Isolation of Compound 1	156
5.1.2.6	Overall Synthesis Summary	157
5.2	Chemistry Development	157
5.2.1	Mechanism of the Sulfoxide-Directed Olefin Reduction	157
5.2.2	Application of the Sulfoxide-Directed Borane Reduction to Other Similar Compounds	160
5.3	Conclusion	162
	Acknowledgments	162
	References	163
6	HIV Integrase Inhibitor: Raltegravir	165
	<i>Guy R. Humphrey and Yong-Li Zhong</i>	
6.1	Project Development	166
6.1.1	Medicinal Chemistry Route	166
6.1.1.1	Advantages of the Medicinal Chemistry Route	167
6.1.1.2	Problems with the Medicinal Chemistry Route	167
6.1.2	Process Development	168
6.1.2.1	First Generation Manufacturing Process for the Synthesis of 1	168
6.1.2.2	Second Generation Manufacturing Process for the Synthesis of 1	177
6.2	Further Chemistry Development	183
6.2.1	Development of Microwave-Accelerated Thermal Rearrangement	183
6.2.2	Mechanistic Studies on the Thermal Rearrangement	185
6.3	Conclusion	189
	Acknowledgments	189
	References	190

7	Cyclopentane-Based NK1 Receptor Antagonist	191
	<i>Jeffrey T. Kuethe</i>	
7.1	Project Development Compound 1	192
7.1.1	Medicinal Route	192
7.1.1.1	Problems of the Original Route	193
7.1.2	Process Development	194
7.1.2.1	Preparation of Cyclopentanone 27	195
7.1.2.2	Conversion of Cyclopentenone 27 to Chiral Hydroxy Acid 26	199
7.1.2.3	Etherification of 10	202
7.1.2.4	Preparation of (<i>R</i>)-Nipeotate 76 and Completion of the Synthesis of 1	209
7.2	Chemistry Development	211
7.2.1	Reduction of the Allylic Alcohol 46 with Red-Al®	211
7.2.2	Oxonium Reduction Configuration Issue	213
7.2.3	Ether Bond Formation with Chiral Imidate 67	214
	Acknowledgments	219
	References	219
8	Glucokinase Activator	223
	<i>Artis Klapars</i>	
8.1	Project Development	223
8.1.1	Medicinal Route	223
8.1.1.1	Problems of the Original Route	224
8.1.1.2	Advantages of the Original Route	225
8.1.2	Process Development	225
8.1.2.1	Preparation of Hydroxypyridine Fragment 9	226
8.1.2.2	Enantioselective Preparation of the α -Arylpyrrolidine 12	226
8.1.2.3	Elaboration of 12 to the Final Product 1	230
8.1.2.4	Summary of Process Development	232
8.2	Chemistry Development	232
8.2.1	Development of Enantioselective α -Arylation of <i>N</i> -Boc Pyrrolidines	232
8.2.2	Scope of Enantioselective α -Arylation of <i>N</i> -Boc Pyrrolidines	234
8.2.3	Detailed Examination of the Coupling Reaction	236
8.3	Conclusion	237
	Acknowledgments	238
	References	238
9	CB1R Inverse Agonist—Taranabant	241
	<i>Debra Wallace</i>	
9.1	Project Development	242
9.1.1	Introduction	242
9.1.2	Medicinal Chemistry Route	242
9.1.3	Initial Strategy—Amide Bond Formation as the Final Step	243
9.1.3.1	Amide Bond Formation as the Final Step—Classical Resolution Approach	244

9.1.3.2	Amide Bond Formation as the Final Step—Dynamic Kinetic Resolution	250
9.2	Further Project Development	253
9.2.1	Introduction	253
9.2.2	New Synthetic Approach	254
9.2.2.1	Enol Triflate Synthesis	256
9.2.2.2	Synthesis of a Model Enamide	258
9.2.2.3	Preliminary Hydrogenation Studies	260
9.2.2.4	Formation of an Enol Tosylate	261
9.2.2.5	Amidation of the Enol Tosylate	262
9.2.2.6	Asymmetric Hydrogenation of Enamide 22	265
9.2.2.7	Use of a Bromosubstituted-Enamide	267
9.2.2.8	Use of a “Nitrile Protected” Enamide	268
9.2.3	Evaluation and Route Selection	271
9.3	Conclusion	273
	Acknowledgments	273
	References	273
	Index	275

